Amendment of Solicitation/Modification of Contract 0004, dated February 4, 2020, to Agreement, dated September 10, 2018 by and between SIGA and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

1

4

2. AMENDMENT/MODIFICATION NO.

P00004

3. EFFECTIVE DATE

See Block 16C

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)
ASPR-19-03461

6. ISSUED BY                                                                                                                      CODE

ASPR-BARDA

7. ADMINISTERED BY (If other than Item 6)                                                                   CODE

ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

SIGA TECHNOLOGIES, INC. 1385150
Attn: Daniel Luckshire
SIGA TECHNOLOGIES, INC.
31 East 62nd street
NEW YORK, NY 100658446

(x) 

9A. AMENDMENT OF SOLICITATION NO.

x

10A. MODIFICATION OF CONTRACT/ORDER NO.
HHSO100201800019C

10B. DATED (SEE ITEM 13)

09/10/2018

CODE 1385150

FACILITY CODE

12. ACCOUNTING AND APPROPRIATION DATA (If required)

See Schedule

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE

A.THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

B.THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

X

C.THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

 FAR 43.103 (a) By Mutual Agreement between the parties

D.OTHER (Specify type of modification and authority)

E.IMPORTANT: Contractor☐is not☒is required to sign this document and return _____1___ copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number: 13 ###-###-####

DUNS Number: 932651516

The purpose of this modification P00004 is to revise Article B.2 to:

(a)   Remove Phase 3 multiple dose study, and add TPOXX-phosphate binders
study conduct and PFR formulation development to CLIN 0001

(b) Extend the Base Period of Performance (CLIN 0001) from 09/09/2023 through 12/31/2025

(c) Revise the verbiage for the TPOXX-phosphate binders study and PFR

formulation development in CLIN 0007 to ensure there are no overlaps

in activities between CLIN 0001 and CLIN 0007

See the attached Statement of Work for further details

Continued …

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

Dennis E. Hruby, CSO

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

George J. Keane

15B. CONTRACTOR/OFFEROR

/s/ Dennis E. Hruby

(Signature of person authorized to sign)

15C. DATE SIGNED

27 Jan 2020

16B.UNITED STATES OF AMERICA

/s/ George J. Keane

(Signature of Contracting Officer)

16C. DATE SIGNED

2/4/20

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201800019C/P00004

Page of

2

4

ITEM NO.

(A)

SUPPLIES/SERVICES
(B)

QUANTITY
(C)

UNIT
(D)

UNIT PRICE
(E)

AMOUNT
(F)

All other terms and conditions remain unchanged as a result of this modification

Period of Performance: 09/10/2018 to 09/09/2028

-

PSC: AN13 NAICS: 541714 HHS/BARDA COR is David Simon, ***@***, (202) 260-1101